Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase.

Author(s): Pietila K, Hermens WT, Harmoinen A, Baardman T, Pasternack A, Topol EJ, Simoons ML

Affiliation(s): Clinic of Internal Medicine, Department of Clinical Sciences, Tampere University, Finland.

Publication date & source: 1997-10-15, Am J Cardiol., 80(8):1075-7.

Publication type: Clinical Trial; Randomized Controlled Trial

Peak serum C-reactive protein concentrations were measured in 146 patients randomized to receive streptokinase, alteplase, or a combination of streptokinase and alteplase in the GUSTO-I trial. Those receiving alteplase treatment had lower values than those receiving streptokinase or the combination treatment. Irrespective of treatment, complete reperfusion of the infarct-related artery (TIMI grade 3 flow) was associated with low peak serum C-reactive protein values.